 Epizyme Inc NASDAQ: EPZM and HUTCHMED China Limited NASDAQ: HCM have collaborated to research, develop, manufacture, and commercialize Tazverik tazemetostat in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Tazverik is a methyltransferase inhibitor of EZH2 developed by Epizyme, approved by the FDA for epithelioid sarcoma and certain patients with follicular lymphoma. 